PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424003
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424003
The global pharmaceutical grade lactose market size is expected to reach USD 3.21 billion by 2032, according to a new study by Polaris Market Research. The report "Pharmaceutical Grade Lactose Market Share, Size, Trends, Industry Analysis Report, By Type (Crystalline Monohydrate Lactose, Inhalation Lactose, Granulated Lactose, Spray Dried Lactose), By Region, And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Novel medicines, alternatively known as new or innovative medicines, are pharmaceutical products that are recently developed and distinctively differ from existing medications. These groundbreaking medicines typically involve significant advancements or breakthroughs in medical science and technology. Examples of novel medicines encompass biologics, new chemical entities (NCE), targeted therapies, gene therapies, & immunotherapies. The development of these innovative medicines is propelled by extensive research and development (R&D) efforts undertaken by various drug manufacturing companies globally.
In the realm of pharmaceutical formulations, the inclusion of various excipients is common, and manufacturers are presented with a variety of options. In this landscape, alternative excipients that provide similar functionality and cost advantages may emerge as competitors to a specific product, potentially impacting its market demand.
For instance, EMDEX, as highlighted by the JRS PHARMA. This excipient exhibits promising potential as a feasible alternative to spray-dried lactose, showcasing comparable characteristics concerning powder and tableting properties. This competition among excipients underscores the dynamic nature of the pharmaceutical industry, where the selection of excipients plays a crucial role in formulation development.
European Union (EU) has instituted regulations and incentives to stimulate the growth of the industry and attract investments. As a result, these factors collectively contribute to the expansion, resulting in an augmented demand for products, especially those widely employed in tablets and capsules.
The industry is marked by fierce competition, with numerous companies actively seeking to capture market share and cater to a diverse range of end-users on a global scale. To gain a competitive advantage in this dynamic landscape, it becomes crucial for companies to concentrate on strategic initiatives such as product launches, expansion efforts, and research and development activities.
Leading manufacturers in the market are driven to achieve a heightened level of dominance by engaging in various initiatives that enhance their product offerings, extend their market reach, and foster innovation. This competitive environment underscores the importance of continuous efforts and strategic maneuvers to thrive in the pharmaceutical-grade lactose sector.
The crystalline monohydrate lactose segment dominated the market; this can be attributed to its elevated purity, solubility, and flow properties, to guarantee the safety and effectiveness of their pharmaceutical products.
Asia Pacific will grow rapidly, primarily due to a rise in disposable income, high milk production in the region, and positive support from the government in dairy processing
North America dominated the market on account of the presence of players in the region, well developed pharmaceutical industry, and innovations in the sector
The global players include ARMOR PROTEINES, BASF, Charotar Casein, DFE Pharma, Fengchen, Alpavit, Kavya Pharma, Lactalis Ingredients, Lactose (India), MEGGLE, Friesland Campina, & Surfachem.
Polaris Market Research has segmented the pharmaceutical grade lactose market report based on type, and region: